Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach

Table 3 Independent review of best response (N = 16) according to RECIST criteria

Best response	No	%
Complete response*	1	3.6
Partial response**	1	3.6
Stable disease***	5	28.6
Progressive disease****	9	21.4
Not available for response assessment	12	60.7

* Duration of the complete response was 11 months (breast cancer metastatic to bone and adrenal gland)
** Duration of the partial response was 13.5 months (breast cancer metastatic to bone and liver)
*** Duration of stable disease was +34.1 months (thyroid cancer metastatic to lung), 6.0 months (mesothelioma metastatic to abdomen), 5.1 months (Non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver), and 4.0 months (leiomyosarcoma metastatic to liver).
**** One patient with ovarian cancer had progressive disease while receiving 26 frequencies. She has now stable disease and has been receiving amplitude-modulated electromagnetic fields for +50.5 months (Figure 2).
Not included is a patient with breast cancer metastatic to bone and liver with a near complete response who started systemic chemotherapy with docetaxel and bevacizumab within 4 weeks of experimental treatment initiation.

ISSN: 1756-9966